Lisa Conroy

Lisa Conroy is the Director of Communications at Antidote. She is a seasoned health communications strategist dedicated to understanding the reasons people make the health choices they do, and determining what that means in terms of how scientific data should be communicated. Prior to her role at Antidote, Lisa ran the TEDMED Great Challenges program, a public health initiative funded by RWJF. She also has experience working in pharmaceutical public relations in the areas of respiratory diseases, oncology, and HIV. Lisa holds an MPH from Columbia and a BA in English and International Studies from Northwestern.

How we accelerated a knee osteoarthritis trial by 3 months [case study]

Knee osteoarthritis is the most common form of arthritis worldwide, and its prevalence is expected to continue to rise for years to come. For those that live with this condition, it causes pain, tiredness, loss of flexibility, a grating sensation, bone spurs, and swelling — all constant reminders of the need for new and better treatment options to replace the cartilage that has worn down over ...

Continue reading

How to catch studies up post-COVID: Successfully approaching a rescue trial [whitepaper]

When the pandemic began, more than 1,000 trials were delayed as the focus shifted to minimizing coronavirus exposure and driving COVID-19 vaccine and treatment trials. The reasons were varied — patients weren’t allowed into studies, study starts were delayed, and recruitment was slow. One thing is clear: the impact of these delays on the progress of medical research will likely be felt for years ...

Continue reading

How we launched 3 COVID-19 recruitment projects in an average of 8 days [case study]

As the COVID-19 pandemic surged in late 2020, the urgency of research was felt by all. At Antidote, our mission has always been to enable faster medical innovation by transforming how patients and researchers connect, and we were eager to contribute to the global effort to drive COVID-19 research forward. Our latest patient recruitment case study shares how Antidote contributed to ensuring three ...

Continue reading

Antidote’s Business Development Leader Dave Mauro Named to the 2021 PharmaVOICE 100

We’re thrilled to share that Antidote’s Executive Vice President of Business Development, Dave Mauro, has been named to this year’s PharmaVOICE 100. For sixteen years, the PharmaVOICE 100 has recognized the 100 most inspiring, motivational, and transformational individuals in the life sciences industry as identified by the global community. 

Continue reading

How patient lead generation can accelerate clinical trial patient recruitment [patient recruitment case study]

Postoperative Corneal Induced Chronic Pain (also known as CICP) is a condition that causes chronic pain and blurred vision after eye surgery. For the 300,000 people who experience this, effective treatments could drastically improve their quality of life. 

Continue reading

Clinical research in a post-COVID world: Four sites weigh in on the impact of COVID on the future of medical research [whitepaper]

Over the past year and a half, the traditional clinical research model of patient outreach, in-person screening, and site-based follow-up has had to adjust to drive progress while keeping patients safe. Now, with vaccines driving positivity rates down, we can begin to think about what’s next. Still, questions remain: Of all the changes made in the research industry since the beginning of the ...

Continue reading

How a 67% randomization rate led to 3 months saved in a Parkinson’s trial [patient recruitment case study]

Parkinson’s disease is a disorder of the central nervous system that affects movement, with symptoms such as tremor, slow movement, stiffness, and loss of balance. Current treatments come with side effects, and there is no cure. This means research is critical to developing new and better treatments for the nearly one million people in the US living with Parkinson’s disease. 

Continue reading

COVID-19 and mental health: A look at the pandemic’s impact on mental health, how we’re treating it, and how it’s affecting those in clinical trials [whitepaper]

What impact has COVID-19 had on our collective mental health? How has treatment been adapted to meet new needs? And what does this all mean for clinical trial participants?

Continue reading

Decentralizing research: How reducing patient burden improves trial diversity [whitepaper]

Could the alternative clinical trial approaches necessitated by the COVID-19 pandemic help tip the scales towards fair access to clinical trials? In our latest whitepaper, “Decentralizing research: How reducing patient burden improves trial diversity,” we take a close look at the current state of diversity in clinical trials, then explore how the decreased participant burden of decentralized ...

Continue reading

Patient recruitment: Today’s trends, tomorrow’s potential [interview with ACRPtv]

By some estimations, 80% of clinical trials are delayed or closed because researchers can’t find enough patients to take part in their clinical trials. This, of course, means that trial sponsors are losing money and sites are wasting time screening ineligible patients. But, it also means that countless patients continue to wait for new and potentially better treatment options.

Continue reading

Get our latest posts in your inbox.